Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and in the United States

• Type of Material: Article
• Authors: Daniel Auclair, Multiple Myeloma Res Fdn; Carol Mansfield, RTI Health Solutions, Research Triangle Park; Mark A Fiala, Washington University School of Medicine; Ajai Chari, Icahn School of Medicine; Craig E Cole, MSU Breslin Cancer Center, Lansing; Jonathan Kaufman, Emory University; Gregory J Orloff, Virginia Cancer Specialists, Fairfax; David S Siegel, Hackensack University Medical Center; Jeffrey A Zonder, Barbara Ann Karmanos Cancer Institute, Detroit; Brennan Mange, RTI Health Solutions, Research Triangle Park; Jennifer Yesil, Multiple Myeloma Research Foundation, Norwalk; Mehul Dalal, Millennium Pharmaceuticals, Inc.; Joseph R Mikhael, City of Hope Cancer Center, Phoenix
• Language: English
• Date: 2022-01-01
• Publisher: DOVE MEDICAL PRESS LTD
• Publication Version: Final Published Version
• Copyright Statement: © 2022 Auclair et al.
• License: Creative Commons Attribution-Noncommercial 3.0 Unported
• Final Published Version (URL): http://dx.doi.org/10.2147/PPA.S345906
• Title of Journal or Parent Work: PATIENT PREFERENCE AND ADHERENCE
• Volume: 16
• Start Page: 573
• End Page: 585
• Grant/Funding Information: This work was funded in part by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical International Co., Cambridge, MA. Kimberly Moon of RTI Health Solutions provided project management for the analysis
• Keywords: multiple myeloma; Science & Technology; discrete choice experiment; Life Sciences & Biomedicine; Medicine, General & Internal; caregiver; General & Internal Medicine; DISEASE; QUALITY-OF-LIFE; preference; patient; CANCER; BURDEN; LEUKEMIA
• Research Categories: Health Sciences, Oncology

Abstract

Introduction/Background: This study aimed to describe patient and caregiver preferences for treatments of relapsed or refractory multiple myeloma (MM). Materials and Methods: A survey including discrete-choice experiment (DCE) and best-worst scaling (BWS) exercises was conducted among US patients with relapsed or refractory MM and their caregivers. The DCE included six attributes with varying levels including progression-free survival (PFS), toxicity, and mode and frequency of administration. In addition, the impact of treatment cost was assessed using a fixed-choice question. The BWS exercise included 18 items (modes and frequency of administration, additional treatment convenience, and toxicity items). The survey was administered online to patients recruited from the Multiple Myeloma Research Foundation CoMMpass study (NCT01454297). Results: The final samples consisted of 94 patients and 32 caregivers. Avoiding severe nerve damage was most important to patients, followed by longer PFS. Caregivers considered PFS to be the most important attribute. We estimate that a third or more of patients were cost-sensitive, meaning their treatment preference was altered based on cost implications. Caregivers were not cost-sensitive. The three most bothersome treatment features in the BWS exercise were risk of kidney failure, lowering white blood cell counts, and weakening the immune system. Conclusion: Patients with relapsed or refractory MM and their caregivers consider many factors including efficacy, toxicity, mode/ frequency of administration, and cost in their decisions regarding treatment options. The study provides a basis for future Research on patient and caregiver treatment preferences, which could be incorporated into shared decision-making with physicians.